Renal safety profiles of ibandronate 6 mg infused over 15 and 60 min: a randomized, open-label study.
about
Collapsing focal segmental glomerulosclerosis following long-term treatment with oral ibandronate: case report and review of literatureEvidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone ClubOral ibandronate in metastatic bone breast cancer: the Florence University experience and a review of the literature.Current options for the management of postmenopausal osteoporosis.Endocrine and metabolic emergencies: hypercalcaemia.Effects of zoledronic acid and ibandronic acid on renal functions and calcium, phosphorus and alkaline phosphatase levels in breast cancer patients with bone metastases: a retrospective analysis.
P2860
Renal safety profiles of ibandronate 6 mg infused over 15 and 60 min: a randomized, open-label study.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Renal safety profiles of iband ...... randomized, open-label study.
@en
Renal safety profiles of iband ...... randomized, open-label study.
@nl
type
label
Renal safety profiles of iband ...... randomized, open-label study.
@en
Renal safety profiles of iband ...... randomized, open-label study.
@nl
prefLabel
Renal safety profiles of iband ...... randomized, open-label study.
@en
Renal safety profiles of iband ...... randomized, open-label study.
@nl
P2093
P356
P1433
P1476
Renal safety profiles of iband ...... randomized, open-label study.
@en
P2093
B Bergstrom
B Thürlimann
C B Caspar
K Schmieding
M Pecherstorfer
R von Moos
P304
P356
10.1093/ANNONC/MDN038
P577
2008-03-11T00:00:00Z